MIOLive 2027 aims to provide an important opportunity for international learning and discussion in interventional oncology (IO), with a practical, multidisciplinary, and patient-centred approach. In a field marked by rapid advances in technology, systemic therapies, and locoregional procedures, it is essential to integrate new scientific evidence into clinical practice and identify the most appropriate treatment strategy for each patient.

The programme focuses in particular on the complexity of treatment decisions in hepatocellular carcinoma (HCC), from the use of biomarkers and functional imaging to the sequencing and combination of therapies. Through interactive sessions and case discussions, participants will compare different approaches, examine the indications and limitations of available treatments, and explore how to balance efficacy, toxicity, quality of life, and individual treatment goals.

The congress also addresses innovations in the management of biliary diseases and cholangiocarcinoma, neuroendocrine tumours and their integration with systemic therapies and theranostics, as well as future perspectives in intrahepatic cholangiocarcinoma. The programme also covers cross-cutting topics such as functional liver augmentation, iatrogenic complications, portal and transradial interventions, and intratumoral therapies, highlighting the opportunities created by integrating surgical, oncological, radiological, and interventional approaches.

A further objective is to promote critical evaluation of the evidence and greater consistency in clinical practice. Sessions on guidelines, international consensus, ablation-margin assessment, and assessment tools address the need for shared criteria to ensure effective and safe procedures. Scientific presentations, research projects, and discussions of future directions help connect innovation with real-world clinical needs.

Live case sessions and recorded demonstrations are central to the programme. They enable participants to observe techniques and procedural decisions in real-world settings, share practical experience, and discuss indications, strategies, and challenges. Together with lectures, multidisciplinary panels, and international discussion, these activities support the application of knowledge in everyday clinical practice.

By fostering collaboration among specialists and dialogue across disciplines and regions, MIOLive 2027 aims to advance evidence-based, personalised, and patient-centred interventional care. Its ultimate goal is to improve the quality of clinical decisions, the appropriateness and safety of treatments, and outcomes for patients with hepatic and biliary cancers.